Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Moonshot Round 2 Focuses On Screening; Pharma To Participate In New Summit

Executive Summary

The initial moonshot aimed to increase cancer research while the reboot seeks to boost screenings to reduce death rate. New cancer cabinet mirrors previous task force. Biopharmaceutical companies are to participate in summit to highlight new commitments.

You may also be interested in...



ARPA-H: New Health Research Agency Faces Old Concerns About Disrupting Private Investment

Proposed Advanced Research Project Agency for Health also needs to distinguish itself from NCATS, which faced many of the same questions when it was created a decade ago. Disagreements also persist about whether ARPA-H should be housed in NIH or HHS.

Biden’s ‘Advanced Research’ Agency May Have Pros And Cons, Congressional Research Service Concludes

CRS poses series of questions about how a new federal agency tasked with speeding translational research for treating high-impact diseases would work, including potential downsides and whether it would duplicate government programs already in place.

Cancer 'Moonshot' Recommendations On R&D Have Strong Patient Focus

Blue ribbon panel has plenty of industry-friendly recommendations on ways to accelerate oncology science, but with the clock ticking down on the Obama Administration, the question is whether the recommendations have any political traction.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel